Literature DB >> 7193811

Oral contraceptive history as a risk indicator in patients with pituitary tumors with hyperprolactinemia: a case comparison study of twenty patients.

L Teperman, W Futterweit, R Zappulla, L I Malis.   

Abstract

This report presents a retrospective case comparison study of 20 hyperprolactinemic patients with pituitary adenomas treated at the Mount Sinai Hospital (1976-1079). An association between oral contraceptive (OC) use and 20 subjects with pituitary tumors was substantiated using discordant paired analysis. The comparison group consisted of appendectomy patients admitted during the same time period and matched for sex and age. The estimated relative risk was 4.0 (P less than 0.025). This study suggests that there is a significant association between OC use and pituitary tumors associated with hyperprolactinemia.

Entities:  

Keywords:  Biology; Cancer; Case Histories; Comparative Studies; Contraception; Contraceptive Methods; Data Collection; Diseases; Endocrine System; Family Planning; Hormones; Neoplasms; Oral Contraceptives; Physiology; Pituitary Gland; Pituitary Hormones; Prolactin--analysis; Research Methodology; Studies

Mesh:

Substances:

Year:  1980        PMID: 7193811     DOI: 10.1227/00006123-198012000-00005

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

1.  Effect of estrogens on prolactin secretion in transsexual subjects.

Authors:  H H Goh; S S Ratnam
Journal:  Arch Sex Behav       Date:  1990-10

2.  Prolactinoma in a man following industrial exposure to estrogens.

Authors:  S H Baron; J R Sowers; M Feinberg
Journal:  West J Med       Date:  1983-05

3.  Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses.

Authors:  David J Cote; John L Kilgallon; Noah L A Nawabi; Hassan Y Dawood; Timothy R Smith; Ursula B Kaiser; Edward R Laws; JoAnn E Manson; Meir J Stampfer
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.